Replication of R5SF162 in rectosigmoid tissue was greater than in tonsillar tissue. When recalculated on a per block basis, an average block of R5SF162 HIV-1-infected tonsillar tissue produced between days 3 and 12 postinfection 0.86 ± 0.12 ng of p24, whereas over the same period an average block of rectosigmoid tissue infected with R5SF162 produced 4 ± 0.98 ng of p24. Replication of X4LAI.04 was greater in tonsil blocks than in rectal biopsies with an average production of 26.7 ± 0.8 and 8 ± 1.53 ng of p24 per block of tonsillar and rectosigmoid tissue, respectively.
We compared R5 and X4 replication in matched blocks of tissues; in tonsils, R5SF162 replication was less than X4LAI.04 replication. The total accumulation of p24 in supernatants from R5-infected tonsillar tissues reached 12.4 ± 7.6% of that from X4-infected tissues (Fig. 1e) and the total production of viral RNA from R5-infected tissues constituted 15 ± 9% of that in X4-infected tissues (Fig. 1f). In contrast, in rectosigmoid tissue, R5 and X4 replications were similar, with the former reaching 54 ± 17% (P = 0.3) of the latter (n = 5; Fig. 2e,f). This difference between the HIV-1 replication of R5 and X4 in the two types of tissues was not associated with large differences in replication kinetics [18,23].
There were correlations between the accumulation of p24 and RNA within each tissue type. For tonsillar tissues from each donor, the release of p24 strongly correlated with the release of viral RNA: r varied between 0.92 and 0.99 for X4LAI.04 and between 0.95 and 0.999 for R5SF162. The correlation between these two parameters remained strong when data points from five different donors were pooled, r = 0.90, P < 0.001 and r = 0.94, P < 0.001 for X4LAI.04 and R5 isolates, respectively (Fig. 1c,d). For rectosigmoid tissue, the correlation between the production of p24 and viral RNA was not as tight as in tonsils (Fig. 2a,b). This may reflect the larger number of tonsil (27) versus rectosigmoid (four) explants. In individual rectosigmoid experiments, r varied between 0.75 and 0.99 for X4LAI.04-infected tissue and between 0.78 and 0.99 for R5SF162-infected tissue. For pooled experiments r = 0.79, P < 0.001 for X4LAI.04 and r = 0.84, P < 0.001 for R5SF162, respectively (Fig. 2c,d).
Analysis of the infection of rectosigmoid and tonsillar tissues thus revealed similarities in the kinetics of R5 and X4 HIV-1 replication and a strong correlation between p24 and viral RNA release for both viral variants in both types of tissues. Relative R5 replication was much more efficient in rectosigmoid than in tonsillar tissue.
Lymphocyte subsets in rectosigmoid and tonsillar tissue
To compare HIV-1 infection of rectosigmoid and tonsillar tissues at the cellular level, we phenotyped lymphocytes isolated from tissue blocks [19,24]. The resultant cell suspensions were stained for CD45, CD3, CD4, CD8, CCR5, CXCR4, CD19, CD16, CD56, and p24 and subjected to flow cytometry.
In our analysis of tonsillar cell subsets, we pooled 27 or 54 tissue blocks each containing on average 159 380.3 ± 24 469 T cells, which constituted 56 ± 6% of all tissue lymphocytes. CD4 and CD8 T cells accounted for almost the entire CD3 cell subset, with an average ratio of 4.5 ± 0.4 (n = 5). A majority, 66 ± 5%, of CD4 T cells expressed CXCR4 but not CCR5, whereas only 6 ± 2% expressed CCR5 without any apparent expression of CXCR4 and 9 ± 2% expressed both CXCR4 and CCR5 (n = 15; Fig. 3a). On day 12 of culture, there were no significant changes, with T cells constituting 55.2 ± 4.3% (n = 5) of lymphocytes with a CD4: CD8 ratio of 5.7 ± 1.07 (n = 5), and B cells accounting for 29.5 ± 5.7% of lymphocytes (n = 5). Further analysis showed that 70 ± 4% of CD4 T cells expressed CXCR4, whereas only 5.4 ± 1% of CD4 T cells exclusively expressed CCR5. Only 3.36 ± 0.6% of CD4 T cells were double positive, whereas the remaining cells were double negative (n = 19).
An average block of rectosigmoid tissue contained 367 820 ± 76 394 T cells, which constituted 60 ± 10% of lymphocytes, whereas B cells constituted 32 ± 10% of lymphocytes. CD4 and CD8 T cells accounted for almost the entire CD3 cell subset, with an average CD4: CD8 ratio of 2.3 ± 0.5 (n = 5). HIV-1 co-receptor expression on rectosigmoid CD4 T cells was in agreement with previous reports from our group [21,25,26]; 11 ± 3% of CD4 T cells expressed CXCR4 only, 31 ± 5% selectively expressed CCR5, and 40 ± 8% expressed both CXCR4 and CCR5 (Fig. 3b).
At days 7–10 of culture, T cells made up 86 ± 6% and B cells 11 ± 5% of lymphocytes (n = 4). The distribution of T-cell subsets was similar to that observed at day 0, the average CD4: CD8 ratio remained at the level of 2.54 ± 0.34 (n = 4). The expression of chemokine receptors changed slightly from that in freshly isolated tissues and reflected an increase in CXCR4 expression, with 36.3% of CD4 T cells exclusively expressing CXCR4, 47.8% expressing both CXCR4 and CCR5, whereas 12% of CD4 T cells exclusively expressed CCR5.
HIV-1 infection of tonsillar and rectal tissue
HIV-1 infection of both tissues resulted in CD4 T-cell depletion. In tonsils, X4LAI.04 infection depleted 80 ± 1% of CD4 T cells (n = 3, P = 0.026), whereas R5SF162 infection depleted 4.57 ± 4.54% (n = 3, P = 0.9) of CD4 T cells (Fig. 4a). In rectosigmoid tissue, X4LAI.04 infection depleted 79 ± 6% (P = 0.02, n = 3) of CD4 T cells, whereas R5SF162 depleted 34 ± 7% (P = 0.05, n = 3) of these cells (Fig. 4b).
HIV-1-infected CD4 T lymphocytes were identified by intracellular p24 staining. To include CD4 T cells that downregulated CD4 cells because of HIV-1 infection, we analysed CD3+CD8− cells because almost all T cells in uninfected tissue express either CD4 or CD8. In tonsillar tissues on day 12 post-X4LAI.04 infection, 4.7 ± 1.7% (n = 5, P = 0.025) of CD3+CD8− cells were p24-positive, whereas in tissues infected with R5SF162 the p24-positive fraction constituted 1.22 ± 0.3% (n = 5, P < 0.01) of these cells. In X4LAI.04-infected rectosigmoid tissue, 10 ± 5% (n = 5) of CD3+CD8− lymphocytes were p24-positive, whereas in matched samples infected with R5SF162, 3.47 ± 1.57% (n = 5) of these cells were p24 positive.
The frequency of CCR5+CD4+ T cells in rectosigmoid tissue was approximately fivefold greater than in tonsillar tissue and, accordingly, the frequency of R5 HIV-1 productively infected CD4 T cells was greater in rectosigmoid compared with tonsillar tissue.
Cytokines of rectosigmoid and tonsillar tissue
We analysed the modulation of cytokine secretion by HIV-1 infection in rectosigmoid tissues because such a modulation in human tonsils was previously documented .
As was shown earlier and confirmed here (Fig. 5), the infection of tonsillar tissue with X4LAI.04 increased the secretion of four measured chemokines: from the basal level of 901 ± 120 pg/ml, MIP-1β increased 8.95 ± 1.14-fold (P < 0.001), MIP-1α increased 4.30 ± 1.11-fold (basal level 479 ± 70 pg/ml, P < 0.001) and RANTES increased 2.5-fold (basal level 1256 ± 437 pg/ml, n = 5), although the increase in the latter chemokine was not statistically significant. SDF-1α increased 5.57 ± 0.5-fold (basal level 1295 ± 286 pg/ml, P < 0.001). Also, X4LAI.04 infection increased the secretion of TNF-α 1.65 ± 0.24-fold (basal level 77 ± 4 pg/ml, P = 0.024) and IFN-γ 2.07 ± 0.24-fold (basal level 253 ± 33 pg/ml, P < 0.001). There was no increase in IL-1α, IL-1β, IP-10, IL-10 or MIG. Notably, R5SF162 did not change the production of any of the tested chemokines/cytokines.
In rectosigmoid tissue, neither X4LAI.04 nor R5SF162 modulated the production of chemokines; RANTES, MIP-1α and MIP-1β remained at the basal levels of 1700 ± 167 pg/ml, 7189 ± 900 pg/ml and 25 553 ± 5102 pg/ml, respectively. The production of several cytokines increased upon HIV-1 infection: IP-10 increased 10.21 ± 3.7-fold (P < 0.001) in X4LAI.04 and 12.22 ± 6.6-fold (P = 0.003) in R5SF162-infected tissues from a basal level of 5067 ± 2348 pg/ml; MIG increased 5.13 ± 1.5-fold (P < 0.001) in X4LAI.04-infected tissues and 25.4 ± 19-fold (P ≤ 0.001) in R5SF162-infected tissues from a basal level of 39.6 ± 27.6 ng/ml and IL-10 increased 17 ± 9-fold (P = 0.003) in X4LAI.04 and 20.39 ± 11-fold in R5SF162-infected tissues from a basal level of 1565 ± 884 pg/ml.
To test whether the lack of HIV-1-mediated chemokine induction in rectosigmoid tissue was caused by an inherent incapacity to secrete these chemokines, we activated ex vivo rectosigmoid cultures with phytohemaglutinin and measured the secretion of β chemokines. A 3-day phytohemaglutinin activation (10 μg/ml) increased chemokine secretion over the next 7 days: MIP-1β increased 23.1 ± 9.8-fold, MIP-1α increased 11.9 ± 4.4-fold and RANTES increased 16.25 ± 3.56-fold (n = 3). The α chemokine SDF-1α was increased 20.5 ± 9.7-fold. Rectosigmoid tissue ex vivo is thus capable of chemokine secretion upon stimulation, but in contrast to tonsillar tissue fails to do this in response to HIV-1 infection.
Therefore, in rectosigmoid tissue, neither X4 nor R5 upregulate co-receptor blocking chemokines in contrast to tonsillar tissue, in which X4 infection does. In both types of tissues, however, several immunomodulatory cytokines were upregulated in the course of HIV-1 infection.
Whereas both X4 and R5 HIV-1 variants are commonly present in body fluids, R5 HIV-1 is thought to initiate infection selectively, predominantly in lymphoid tissue and dominates its early stages . GALT was recently shown to be the main primary target for HIV-1 at the earliest stages of infection [10–12], not only in cases of anal intercourse but also in other routes of viral transmission. In secondary lymphoid organs, such as lymph nodes or tonsils, infection is established more slowly and viral replication may continue for years .
To test whether GALT is particularly vulnerable to R5 HIV-1 infection, we compared infection by R5 and X4 in the tonsils, a secondary lymphoid organ, and in rectosigmoid tissue ex vivo. Both human tonsillar and rectosigmoid tissues ex vivo support productive infection by R5 and X4 HIV-1 without exogenous stimulation. Another human rectosigmoid explant system was developed earlier by the Dezzutti group for microbicide testing , but it requires phytohemaglutinin activation for efficient HIV-1 infection, probably because the semi-polarization of explants in matrigel  reduces HIV-1 accessibility to lymphocytes.
Although the absolute levels of HIV-1 replication significantly varied from donor to donor, the relative replication levels of the two viruses in tissues from different donors were similar . This allowed us to pool together data from experiments with different donors.
An average block of rectosigmoid tissue produced more R5 and less X4 HIV-1 than a tonsillar tissue block. On the basis of the CD4 T-cell number, p24 production in tonsils was four to seven times greater than in rectosigmoid tissue for both R5 and X4. The measurement of the relative production of X4 and R5 HIV-1 seems to be more adequate. The fraction of CCR5-expressing cells in rectosigmoid tissue was five times greater than in tonsillar tissue. The majority of these cells in rectosigmoid tissue also expressed CXCR4. The expression of CCR5 by CXCR4-positive CD4 T cells may reflect their constitutive activation in GALT . Also, memory CCR5-positive CD4 T cells are prevalent in rectosigmoid tissue . Therefore, in rectosigmoid tissue, R5 potential targets were much more abundant than in tonsillar tissue. Also, other factors, including a twofold difference in the fraction of CD8 cell anti-HIV factor (CAF)-producing CD8 T cells [31,32] may contribute to the difference in replication in tonsillar and rectosigmoid tissues.
To enumerate the actual R5 and X4 targets we identified them by intracellular p24 staining. The number of productively R5-infected lymphocytes was significantly greater in rectosigmoid than in tonsillar tissue, in agreement with the greater replication of R5 in this tissue. Unfortunately, these data do not provide a basis for the comparison of viral productivity of individual R5 and X4-infected cells in tonsillar and rectosigmoid tissue, because p24 measurement in culture medium represents a cumulative production of virus between media changes, whereas intracellular p24 staining is a snapshot of productive cells that have not yet died from infection.
The relative replication levels of R5 HIV-1 in both tissues correlated with the frequency of CCR5-positive T cells, which in rectosigmoid tissue constituted approximately 70% of the total CD4 T cells at the time of infection, whereas in tonsillar tissue, on average, these cells made up approximately 15% of CD4 T cells. This difference provides the simplest explanation for the difference in the efficiency of R5 HIV-1 infection in these tissues. The abundance of CCR5-positive CD4 T cells in rectosigmoid tissue makes the cytopathic impact of R5 more pronounced than in tonsillar tissue. In the latter, R5 depletion is barely noticeable, whereas in rectosigmoid tissue more than 34% of CD4 T cells were depleted. These data may be relevant to the predominant mucosal transmission of R5 virus and the rapid depletion of GALT T lymphocytes at the early stages of HIV-1 infection.
Although R5 replicated more efficiently in rectosigmoid compared with tonsillar tissue, in both tissues X4 targets, the CXCR4-positive CD4 T lymphocytes, comprise the majority of the CD4 T cell population [21,33,34], and both tissues support X4 infection. With the improvement in staining techniques, it becomes apparent that virtually all the CD4 T cells are potential targets for X4.
In addition to the chemokine receptors, chemokines themselves may modulate HIV-1 infection as one of the first lines of antimicrobial defence. The upregulation of chemokines occurs in human tonsillar tissue ex vivo upon X4 but not R5 HIV-1 infection. It thus appears that at a local level, secondary lymphoid tissue is capable of mounting a defence, although not broadly effective, as X4 largely upregulates MIP-1α, MIP-1β and RANTES that do inhibit R5 rather than X4 .
In rectosigmoid tissue, the basal level of chemokines is greater than in tonsillar tissue, and might be thought to be an obstacle to R5 infection. Nevertheless, as shown here, rectosigmoid tissue is readily infected by R5. It is conceivable that, because of the high expression of CCR5, the basal levels of CCR5 ligands in rectosigmoid tissue might not saturate this receptor to inhibit HIV-1 entry. In addition, X4 infection in rectosigmoid tissue does not upregulate chemokine secretion (as it does in the tonsils). This lack of upregulation is not because rectosigmoid tissue is unable to upregulate chemokines further as we demonstrated with phytohemaglutinin stimulation. The inability of rectosigmoid tissue to upregulate cytokines in response to HIV-1 infection may render it more vulnerable to HIV-1 than secondary lymphoid tissue.
Also, it is conceivable that the spikes of X4 in secondary lymphoid tissue demonstrated by Mullins et al.  may upregulate CC chemokines, thus suppressing R5, whereas in gut tissue, where X4 fails to upregulate chemokine release, there is no such suppressive mechanism.
In conclusion, by comparing tonsillar and rectosigmoid tissue susceptibility to R5 and X4 HIV-1, we showed that the latter is more susceptible to R5 infection than the former. This difference seems to be related to the much greater expression of CCR5 co-receptors in rectosigmoid than in tonsillar tissue. The majority of rectosigmoid CD4 lymphocytes still express CXCR4, however, either alone or in combination with CCR5, and therefore this tissue is also readily infected with X4 ex vivo. This strongly suggests that co-receptor expression alone is not sufficient to explain the R5 predominance seen in early infection. Undoubtedly, there are additional mechanisms that serve as partial ‘gatekeepers’ restricting X4 infection in vivo .
The authors would like to thank Dr M. Santi and the entire staff of the Department of Pathology of the Children's National Medical Center for their generous assistance in obtaining human tonsillar tissues.
Sponsorship: This research was partly supported by the Intramural Research Program of the NIH, National Institute of Child Health and Human Development, NIH Intramural funds, NIH NIAID U19 IP/CP for microbicide research (AI060614), the Oppenheimer Brothers' Foundation and the NIH CFAR Cores at UCLA of Mucosal Immunology, Flow Cytometry and Virology (AI#28697).
1. Fauci AS. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 1993; 262:1011–1018.
2. Pantaleo G, Graziosi C, Demarest JF, Cohen OJ, Vaccarezza M, Gantt K, et al
. Role of lymphoid organs in the pathogenesis of human immunodeficiency virus (HIV) infection. Immunol Rev 1994; 140:105–130.
3. Epstein LG, Kuiken C, Blumberg BM, Hartman S, Sharer LR, Clement M, Goudsmit J. HIV-1 V3 domain variation in brain and spleen of children with AIDS: tissue-specific evolution within host-determined quasispecies. Virology 1991; 180:583–590.
4. Jung A, Maier R, Vartanian JP, Bocharov G, Jung V, Fischer U, et al
. Recombination: multiply infected spleen cells in HIV patients. Nature 2002; 418:144.
5. Falk S, Stutte HJ. The spleen in HIV infection – morphological evidence of HIV-associated macrophage dysfunction. Res Virol 1990; 141:161–169.
6. Haase AT, Henry K, Zupancic M, Sedgewick G, Faust RA, Melroe H, et al
. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 1996; 274:985–989.
7. Frankel SS, Tenner-Racz K, Racz P, Wenig BM, Hansen CH, Heffner D, et al
. Active replication of HIV-1 at the lymphoepithelial surface of the tonsil. Am J Pathol 1997; 151:89–96.
8. Kaminski B, Janicki K, Wiech AD. The case of a great pharyngeal tonsil hypertrophy in a twenty-one-year-old patient infected with HIV virus [in Polish]. Otolaryngol Pol 2004; 58:977–979.
9. Veazey RS, DeMaria M, Chalifoux LV, Shvetz DE, Pauley DR, Knight HL, et al
. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 1998; 280:427–431.
10. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, et al
. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200:749–759.
11. Veazey RS, Lackner AA. HIV swiftly guts the immune system. Nat Med 2005; 11:469–470.
12. Chase A, Zhou Y, Siliciano RF. HIV-1-induced depletion of CD4+ T cells in the gut: mechanism and therapeutic implications. Trends Pharmacol Sci 2006; 27:4–7.
13. Olsson J, Poles M, Spetz AL, Elliott J, Hultin L, Giorgi J, et al
. Human immunodeficiency virus type 1 infection is associated with significant mucosal inflammation characterized by increased expression of CCR5, CXCR4, and beta-chemokines. J Infect Dis 2000; 182:1625–1635.
14. Delwart EL, Mullins JI, Gupta P, Learn GH Jr, Holodniy M, Katzenstein D, et al
. Human immunodeficiency virus type 1 populations in blood and semen. J Virol 1998; 72:617–623.
15. Pillai SK, Good B, Pond SK, Wong JK, Strain MC, Richman DD, Smith DM. Semen-specific genetic characteristics of human immunodeficiency virus type 1 env. J Virol 2005; 79:1734–1742.
16. Fletcher PS, Elliott J, Grivel JC, Margolis L, Anton P, McGowan I, Shattock RJ. Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides. AIDS 2006; 20:1237–1245.
17. Glushakova S, Baibakov B, Margolis LB, Zimmerberg J. Infection of human tonsil histocultures: a model for HIV pathogenesis. Nat Med 1995; 1:1320–1322.
18. Glushakova S, Baibakov B, Zimmerberg J, Margolis L. Experimental HIV infection of human lymphoid tissue: Correlation of CD4+ T cell depletion and virus syncytium-inducing/non-syncytium-inducing phenotype in histoculture inoculated with laboratory strains and patient isolates of HIV type 1. AIDS Res Retroviruses 1997; 13:461–471.
19. Shacklett BL, Yang O, Hausner MA, Elliott J, Hultin L, Price C, et al
. Optimization of methods to assess human mucosal T-cell responses to HIV infection. J Immunol Methods 2003; 279:17–31.
20. Grivel JC, Biancotto A, Ito Y, Lima RG, Margolis LB. Bystander CD4+ T lymphocytes survive in HIV-infected human lymphoid tissue. AIDS Res Hum Retroviruses 2003; 19:211–216.
21. Grivel JC, Margolis LB. CCR5- and CXCR4-tropic HIV-1 are equally cytopathic for their T-cell targets in human lymphoid tissue. Nat Med 1999; 5:344–346.
22. Ito Y, Grivel JC, Margolis L. Real-time PCR assay of individual human immunodeficiency virus type 1 variants in coinfected human lymphoid tissues. J Clin Microbiol 2003; 41:2126–2131.
23. Ito Y, Grivel JC, Chen S, Kiselyeva Y, Reichelderfer P, Margolis L. CXCR4-tropic HIV-1 suppresses replication of CCR5-tropic HIV-1 in human lymphoid tissue by selective induction of CC-chemokines. J Infect Dis 2004; 189:506–514.
24. Grivel JC, Santoro F, Chen S, Faga G, Malnati MS, Ito Y, et al
. Pathogenic effects of human herpesvirus 6 in human lymphoid tissue ex vivo
. J Virol 2003; 77:8280–8289.
25. Anton PA, Elliott J, Poles MA, McGowan IM, Matud J, Hultin LE, et al
. Enhanced levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated using intestinal biopsy tissue. AIDS 2000; 14:1761–1765.
26. Poles MA, Elliott J, Taing P, Anton PA, Chen IS. A preponderance of CCR5(+) CXCR4(+) mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection. J Virol 2001; 75:8390–8399.
27. Margolis L, Shattock R. Selective transmission of CCR5-utilizing HIV-1: the ‘gatekeeper’ problem resolved? Nat Rev Microbiol 2006; 4:312–317.
28. Pantaleo G, Graziosi C, Fauci AS. The role of lymphoid organs in the pathogenesis of HIV infection. Semin Immunol 1993; 5:157–163.
29. Abner SR, Guenthner PC, Guarner J, Hancock KA, Cummins JE Jr, Fink A, et al
. A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection. J Infect Dis 2005; 192:1545–1556.
30. Karlsson I, Grivel JC, Chen SS, Karlsson A, Albert J, Fenyo EM, Margolis LB. Differential pathogenesis of primary CCR5-using human immunodeficiency virus type 1 isolates in ex vivo human lymphoid tissue. J Virol 2005; 79:11151–11160.
31. Levy JA. The search for the CD8+ cell anti-HIV factor (CAF). Trends Immunol 2003; 24:628–632.
32. Mackewicz CE, Blackbourn DJ, Levy JA. CD8+ T cells suppress human immunodeficiency virus replication by inhibiting viral transcription. Proc Natl Acad Sci U S A 1995; 92:2308–2312.
33. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci U S A 1997; 94:1925–1930.
34. Penn ML, Grivel JC, Schramm B, Goldsmith MA, Margolis L. CXCR4 utilization is sufficient to trigger CD4+ T cell depletion in HIV- 1-infected human lymphoid tissue. Proc Natl Acad Sci U S A 1999; 96:663–668.
35. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells [see Comments]. Science 1995; 270:1811–1815.
36. Mullins JI, Jensen MA. Evolutionary dynamics of HIV-1 and the control of AIDS. Curr Top Microbiol Immunol 2006; 299:171–192.
Keywords:© 2007 Lippincott Williams & Wilkins, Inc.
Co-receptor; gut-associated lymphoid tissue; HIV-1; mucosa; tonsil